AcuCort AB has entered into an exclusive licence and distribution agreement with Canadian pharmaceutical company Kye Pharmaceuticals for Zeqmelit®, a rapidly dissolving dexamethasone oral film, in Canada. Under the agreement, AcuCort will receive an upfront payment and milestone payments, revenue from product supply to Kye, and will also be entitled to royalties based on net sales. The agreement represents another important step in AcuCort's international expansion.
The commercial agreement grants Kye Pharmaceuticals exclusive rights to register, market, distribute and sell Zeqmelit® in Canada. The regulatory submission is planned for early 2027. Subject to marketing authorisation from Health Canada, launch is expected in 2028.
The agreement includes an upfront payment, a regulatory milestone, milestone payments and royalties based on net sales, as well as revenue from product supply to Kye.
Kye Pharmaceuticals is a Canadian specialty pharmaceutical company with an established presence in market segments relevant to Zeqmelit®, including multiple therapies for paediatrics. Since 2024, the company has launched seven innovative prescription pharmaceutical products in Canada, demonstrating its experience in bringing new medicines to the Canadian market.
"The agreement is an important step in our international expansion and gives us a commercial partner with relevant experience and an established presence in the Canadian market, which comprises more than 40 million people. At the same time, the agreement establishes a clear revenue model for AcuCort, with an upfront payment and further revenue opportunities linked to milestones and future sales of Zeqmelit®. This is precisely the type of partnership on which our international strategy is based," says Jonas Jönmark, CEO of AcuCort.
John McKendry, CEO of Kye Pharmaceuticals, comments:
"Zeqmelit® is an important strategic addition to our product portfolio and aligns well with our mission to bring innovative medicines to Canadian patients that address significant unmet clinical needs. Zeqmelit® will benefit from our strong sales organisation in paediatrics while also extending our market reach into other therapeutic areas, including allergy and respiratory diseases."
The agreement represents another step in AcuCort's strategy to commercialise Zeqmelit® in prioritised international markets through established commercial partners.
Zeqmelit® is currently marketed in Sweden, Denmark, Norway and Finland. AcuCort also has an existing commercial agreement with Glenmark Pharmaceuticals for Zeqmelit® in Germany, the Netherlands, the Czech Republic, Austria, Slovakia and Ukraine.
About Kye Pharmaceuticals
Kye is a leading specialty pharmaceutical company committed to bringing value to Canadians by identifying, licensing, and commercializing novel prescription medicines that may not otherwise be available to patients across Canada. With a growing pipeline of innovative medicines, Kye's portfolio spans a range of therapeutic areas including cardiology, psychiatry, pediatrics, rare diseases, neuromuscular, hematology, and neurology. Kye Pharmaceuticals is a private company, founded in Canada and focused exclusively on the healthcare needs of patients in Canada. Kye aims to provide medicines that deliver better outcomes to our partners, healthcare professionals, and most importantly, patients across Canada. Kye, headquartered in Mississauga, Ontario was recognized on the Globe & Mail list of Canada's Top Growing Companies for 2025 and 2026.
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
This information constitutes information that AcuCort is obligated to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the above contact person's provision, on 2026-11-09
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.